AR016666A1 - Derivados de pirimidinona, un procedimiento para su preparacion y una composicion farmaceutica que los contiene - Google Patents

Derivados de pirimidinona, un procedimiento para su preparacion y una composicion farmaceutica que los contiene

Info

Publication number
AR016666A1
AR016666A1 ARP980105567A ARP980105567A AR016666A1 AR 016666 A1 AR016666 A1 AR 016666A1 AR P980105567 A ARP980105567 A AR P980105567A AR P980105567 A ARP980105567 A AR P980105567A AR 016666 A1 AR016666 A1 AR 016666A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
aryl
monofluoro
perfluoro
Prior art date
Application number
ARP980105567A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9723358.9A external-priority patent/GB9723358D0/en
Priority claimed from GBGB9723352.2A external-priority patent/GB9723352D0/en
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR016666A1 publication Critical patent/AR016666A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Derivados de pirimidinona, que comprenden los compuestos de la formula (I) en la que Z es un enlace y R1 es halogeno; o Z es CR3R4, donde R3 y R4 son cadauno hidrogeno o un alquilo C1-4, o R3 y R4 junto con el átomo de carbono que interviene, formanun anillo cicloalquilo C3-6; y R1 es un grupo arilo oheteroarilo, opcionalmente sustituido con 1, 2, 3 o 4 sustituyentes seleccionados entre alquilo C1-18, alcoxi C1-18, tioalquilo C1-18, alcoxi C1-18, arilo,oxo, hidroxi, halogeno, CN, COR5, COOR5, CONR5R6, NR5COR6, SO2NR5R6, NR5SO2R6, NR5R6, monofluoro-alquilo C1-4 a perfluoro-alquilo C1-4 y monofluoro-alcoxi C1-4a perfluoro-alcoxi C1-4 heteroarilo se refiere a un sistema de anillo heteroaromático o bicíclico que contiene hasta cuatro,preferiblmeente 1 o 2 heteroátomos,seleccionado cada uno entre oxígeno, nitrogeno y azufre; teniendo cada anillo de 4 a 7, preferiblemente 5 o 6, átomos en el anillo, pudiendo un sistema deanillo heteroaromático bicíclico incluir un anillo carbocíclico, X esO o S; Y es un grupo de formula -A1-A2-A3 en la que A1 y A3 representan cada uno unenlace o un grupo alquileno C1-10 de cadena lineal o ramificada y A2 representa un enlace o es O, S, SO, SO2, CO, C=CH2, CH=CH, C:::C, CONH, NHCO o CR5R6, acondicionde que cuando A2 es O, S, SO, SO2 o CONH, A3 contiene como mínimo 2 átomos de C que unen el grupo A2 y el grupo CH2 de la formula (I); R2 es un grupoarilo o heteroarilo,opcionalmente sustituido con1,2,3 o 4 sustituyentes seleccionados entre los sustituyentes definidos anteriormente para R1 y también ariloo alquil C1-4-arilo; W es un enlace y R7 es H; o W es SO2 o un enlace; y R7 es R1 o un grupo hidrocarbonado,cuyo grupo hidrocarbonado puede estar opcionalmenteinterrumpido dentro de la cadena deC por un grupo seleccionado entre O, COO, OCO, CO, CONR8, NR8CO, NR8CONR9, NR8COO, OCONR8 y NR8,y cuyo grupo hidrocarbonadopuede estar opcionalmente sustituido con 1 o 2 sustituyentes seleccionados entre monofluoro-alquilo C1-4 a perfluoro-alquilo C1-4, OR8, COOR8, CONR8R9,NR8COR9,NR8CONR9R10, NR8COOR9, OCONR8R9, NR11R12 y R1; R5 y R6 son independientemente hidrogeno o alquilo C1-20, por ejemplo alquilo C1-4 (por ejemplo metilo o etilo)
ARP980105567A 1997-11-06 1998-11-04 Derivados de pirimidinona, un procedimiento para su preparacion y una composicion farmaceutica que los contiene AR016666A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9723358.9A GB9723358D0 (en) 1997-11-06 1997-11-06 Novel compounds
GBGB9723352.2A GB9723352D0 (en) 1997-11-06 1997-11-06 Novel compounds

Publications (1)

Publication Number Publication Date
AR016666A1 true AR016666A1 (es) 2001-07-25

Family

ID=26312554

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980105567A AR016666A1 (es) 1997-11-06 1998-11-04 Derivados de pirimidinona, un procedimiento para su preparacion y una composicion farmaceutica que los contiene

Country Status (9)

Country Link
US (2) US6417192B1 (es)
EP (1) EP1028955B1 (es)
JP (1) JP2001522844A (es)
AR (1) AR016666A1 (es)
AU (1) AU1157599A (es)
CA (1) CA2309177A1 (es)
DE (1) DE69816471T2 (es)
ES (1) ES2203988T3 (es)
WO (1) WO1999024420A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1105377B1 (en) * 1998-08-21 2003-10-08 SmithKline Beecham plc Pyrimidinone derivatives for the treatment of atherosclerosis
GB9910079D0 (en) * 1999-05-01 1999-06-30 Smithkline Beecham Plc Novel compounds
AU766003B2 (en) 1999-05-01 2003-10-09 Smithkline Beecham Plc Pyrimidinone compounds
GB9910378D0 (en) * 1999-05-05 1999-06-30 Smithkline Beecham Plc Novel compounds
AU3546601A (en) 2000-02-16 2001-08-27 Smithkline Beecham Plc Pyrimidine-4-one derivatives as LDL-PLA<sub>2</sub> inhibitors
GB0024808D0 (en) * 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0024807D0 (en) * 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0119793D0 (en) * 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel compounds
GB0127139D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127143D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0208280D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
GB0208279D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
EP2977452A3 (en) 2007-05-11 2016-05-25 Thomas Jefferson University Methods of treatment and prevention of neurodegenerative diseases and disorders
MX2009012197A (es) 2007-05-11 2010-01-15 Univ Pennsylvania Metodos para tratamiento de ulceras en la piel.
US8691866B2 (en) 2008-12-10 2014-04-08 The General Hospital Corporation HIF inhibitors and use thereof
AU2010232923A1 (en) * 2009-04-03 2011-11-03 Medisyn Technologies, Inc. Compositions for treatment of Alzheimer's disease
TW201209043A (en) * 2010-05-17 2012-03-01 Glaxo Group Ltd Novel processes
JP2013544854A (ja) 2010-12-06 2013-12-19 グラクソ グループ リミテッド 化合物
MX2013006342A (es) * 2010-12-06 2013-08-26 Glaxo Group Ltd Compuestos de pirimidinona para usarse en el tratamiento de enfermedades o afecciones mediadas por fosfolipasa asociada con lipoproteinas a2 (lp-pla2).
US20130267544A1 (en) 2010-12-17 2013-10-10 Peter Adamson Use of LP-PLA2 Inhibitors in the Treatment and Prevention of Eye Diseases
US20140171431A1 (en) * 2011-06-27 2014-06-19 Jianhua Shen Azole heterocyclic compound, preparation method, pharmaceutical composition and use
WO2013013503A1 (en) 2011-07-27 2013-01-31 Glaxo Group Limited 2,3-dihydroimidazo[1,2-c] pyrimidin-5(1h)-one compounds use as lp-pla2 inhibitors
EP2736908A1 (en) 2011-07-27 2014-06-04 Glaxo Group Limited Bicyclic pyrimidone compounds
SG11201505520WA (en) 2013-01-25 2015-08-28 Glaxosmithkline Ip Dev Ltd 2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1H)-ONE BASED LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA<sb>2</sb>) INHIBITORS
EP2948456A4 (en) 2013-01-25 2016-09-14 Glaxosmithkline Ip Dev Ltd BICYCLIC PYRIMIDONE COMPOUNDS AS LP-PLA2 INHIBITORS
CN105008365B (zh) 2013-01-25 2017-03-15 葛兰素史密斯克莱知识产权发展有限公司 化合物
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
BR112017022654A2 (pt) * 2015-04-24 2018-07-10 Shionogi & Co., Ltd. derivado heterocíclico de 6 membros e composição farmacêutica compreendendo o mesmo
EP3133065A1 (en) 2015-08-21 2017-02-22 Merck Patent GmbH Compounds for optically active devices
JP6692113B2 (ja) * 2016-10-21 2020-05-13 塩野義製薬株式会社 ６員複素環誘導体を含有する医薬組成物
EP3363793A1 (en) 2017-02-15 2018-08-22 Merck Patent GmbH Hydrophobic compounds for optically active devices
CN107382726A (zh) * 2017-08-02 2017-11-24 东南大学成贤学院 一种(e)‑2‑(甲氧基亚甲基)‑4‑芳基正丁酯的制备方法
AU2020379796C1 (en) 2019-11-09 2024-05-02 Shanghai SIMR Biotechnology Co., Ltd Tricyclic dihydroimidazopyrimidone derivative, preparation method therefor, pharmaceutical composition and use thereof
WO2022012798A1 (en) 2020-07-15 2022-01-20 Merck Patent Gmbh Optically active devices
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4154834A (en) * 1975-12-29 1979-05-15 Smith Kline & French Laboratories Limited Substituted isocytosines having histamine H2 -antagonist activity
GB1582527A (en) 1975-12-29 1981-01-07 Smith Kline French Lab Pyrimidone and thiopyrimidone derivatives
DE2739193A1 (de) * 1977-08-31 1979-03-08 Bayer Ag Indan-5-yl-n-alkyl-carbaminsaeureester, verfahren zu ihrer herstellung sowie ihre verwendung als pflanzenschutzmittel
JPS6050191B2 (ja) * 1978-04-07 1985-11-07 三共株式会社 ５↓−フルオロウラシル誘導体
US4352933A (en) 1981-02-06 1982-10-05 Smithkline Beckman Corporation Chemical methods and intermediates for preparing substituted pyrimidinones
DE3803063A1 (de) * 1988-01-29 1989-08-10 Schering Ag Thioharnstoffderivate, verfahren zu ihrer herstellung sowie ihre verwendung fuer die neutroneneinfangtherapie von malignen melanomen
HU203736B (en) 1989-04-06 1991-09-30 Gyogyszerkutato Intezet Process for producing new thiouracil-derivatives and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
ES2203988T3 (es) 2004-04-16
DE69816471D1 (de) 2003-08-21
US6417192B1 (en) 2002-07-09
DE69816471T2 (de) 2004-05-27
WO1999024420A1 (en) 1999-05-20
JP2001522844A (ja) 2001-11-20
AU1157599A (en) 1999-05-31
US20020120139A1 (en) 2002-08-29
EP1028955B1 (en) 2003-07-16
CA2309177A1 (en) 1999-05-20
EP1028955A1 (en) 2000-08-23

Similar Documents

Publication Publication Date Title
AR016666A1 (es) Derivados de pirimidinona, un procedimiento para su preparacion y una composicion farmaceutica que los contiene
CO5070570A1 (es) DERIVADOS DE TIROSINA COMO ACTIVADORES DE hPPAR Y hPPARalfa Y UNA COMPOSICION FARMACEUTICA QUE LOS CONTIENE
AR004516A1 (es) Derivados de pirimidina, su uso, procedimientos para prepararlos y medicamentos que los contienen
YU21590A (sh) Derivati benzokondenziranih, n vsebujočih heterociklov in postopek za njihovo pripravo
ES2058531T3 (es) Amidas de mercapto-fenilalcanoilaminoacidos, su preparacion y su uso como inhibidores de colagenasa.
ES557783A0 (es) Un procedimiento para la preparacion de derivados de b-lactama
ES2055115T3 (es) Derivados de fenil-amidina y fenil-guanidina sustituidos en posicion orto y agentes antidiabeticos y hipoglicemicos que los contienen.
DK420682A (da) Fremgangsmaade til fremstilling af triazoloquinazoloner eller salte deraf
AR029308A1 (es) Compuestos de sulfonamidas, composiciones farmaceuticas formuladas con dichos compuestos y uso de los compuestos mencionados para la preparacion de dichas composiciones para potenciar la funcion glutamato receptora
ES2159943T3 (es) Neuvos derivados de piridina y composiciones farmaceuticas que los contienen.
DE3667789D1 (de) Piperazin-1-yl-ergolinderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
DK149270C (da) Analogifremgangsmaade til fremstilling af beta-carbolin-3-carboxylsyrederivater
ES2077042T3 (es) Derivados de benzoxazina, derivados de benzotiazina y herbicidas que comprenden los mismos.
ATE291577T1 (de) Cyanoindol-derivate als inhibitoren der wiederaufnahme von serotonin, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zubereitungen
PT92494A (pt) Processo para a preparacao de novos derivados do indol
PT99250A (pt) Processo para a preparacao de derivados de piperazina
NO872982L (no) Nye tetracykliske indolderivater.
AR043309A1 (es) Compuestos de spiropyrazole